You are here
VENTRIX INCORPORATED
UEI: GZK6V6LL3SM8
# of Employees: 0
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI
Amount: $552,109.00Summary Heart failure post-myocardial infarction (MI) continues to be the leading cause of death in the U.S. Each year it is estimated that ~550K Americans will have a new MI, and ~200K will have a re ...
SBIRPhase II2023Department of Health and Human Services National Institutes of Health -
New infusible ECM hydrogel for treating acute myocardial infarction
Amount: $791,543.00Summary Heart failure post-myocardial infarction (MI) continues to be the leading cause of death in the U.S. Each year it is estimated that ~550K Americans will have a new MI, and ~200K will have a re ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
Phase IIB: Percutaneous deliverable biomaterial for treating myocardial infarction
Amount: $1,026,130.00DESCRIPTION provided by applicant Heart failure following a myocardial infarction MI continues to remain a leading killer in the western world In the United States the estimated annual incidenc ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Phase II: Percutaneous deliverable biomaterial for treating myocardial infarction
Amount: $2,059,825.00DESCRIPTION (provided by applicant): Heart failure following a myocardial infarction (MI) continues to remain a leading killer in the western world. In the United States, the estimated annual incidenc ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Percutaneous deliverable biomaterial for treating myocardial infarction
Amount: $496,930.00DESCRIPTION (provided by applicant): Heart failure following a myocardial infarction (MI) continues to remain a leading killer in the western world. In the United States, the estimated annual incidenc ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
SBIR Phase I:Feasibility of a minimally-invasive biomaterial therapy for heart failure
Amount: $180,000.00This Small Business Innovation Research (SBIR) Phase I project will test the feasibility of delivering a biomaterial treatment for myocardial infarction (MI) and heart failure via catheter, thereby pa ...
SBIRPhase I2010National Science Foundation